drugset / Trial / NCT00006232

Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma

NCT00006232

Phase 3 Completed 200 enrolled West of Scotland Lymphoma Group
RandomizedTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective for multiple myeloma. PURPOSE: This randomized phase III trial is comparing two combination chemotherapy regimens to see how well they work in treating patients with stage II or stage III multiple myeloma.

Timeline

Start
1996-10
Primary completion
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule Oral
Subject Doxorubicin Other / unclassified Intravenous
Subject Idarubicin Small molecule Oral
Subject Vincristine Small molecule Intravenous

Indications